Pharmaceuticals

Samsung Biologics receives 2022 CMO Leadership Award in all six categories

INCHEON, South Korea, Feb. 7, 2022 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization (CDMO), announced that it has been selected as a winner of the 2022 CMO Leadership Awards presented by Outsourced Pharma and Life Science ...

2022-02-07 20:00 2030

Ascletis Announces Positive Data of Oral Double Prodrug ASC10 and Its Antiviral Nucleoside Analog ASC10-A Against Omicron Variant

* ASC10-A demonstrated strong in vitro antiviral activity against multiple SARS-CoV-2 virus variants including Omicron * By applying a double prodrug strategy, ASC10's permeability in Caco-2 cells and ASC10's oral bioavailability in monkeys were 3.2-fold and 2.3-fold of Molnupiravir, respecti...

2022-02-07 19:00 3171

The one-component Sputnik Light vaccine has been authorized in India; over 2.5 billion people live in countries that approved Sputnik Light as a standalone vaccine and a universal booster

Sputnik Light will be an important part of India's vaccination program and the fight against mutations of COVID, including Omicron. Sputnik Light has been authorized in more than 30 countries with total population of over 2.5 billion people. MOSCOW, Feb. 7, 2022  /PRNewswire/ --  The Russian Dir...

2022-02-07 08:18 3413

Everest Medicines Announces First Drug Approval of Trodelvy® in Singapore for Second-Line Metastatic Triple-Negative Breast Cancer

SHANGHAI, Feb. 7, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs inAsia...

2022-02-07 08:00 3784

Ascletis Announces U.S. IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors

* The objectives of the U.S. Phase I trial are to find a recommended Phase II dose and obtain preliminary efficacy in patients with advanced solid tumors * The first U.S. patient is expected to be dosed in the first half of 2022 * ASC61 shows significant antitumor efficacy as a single agent i...

2022-02-06 18:30 4127

Vitro S.A. sells Cytognos to BD to prioritize the market launch of their new and disruptive Molecular Biology and Anatomic Pathology diagnostic platforms

Cytognos divestment is a first strategic step aimed at positioning Vitro as a new worldwide diagnostic player in their key market segments SEVILLE, Spain, Feb. 4, 2022 /PRNewswire/ -- Vitro S.A, (www.vitro.bio ) a privately held company headquartered in Seville, Spain, ann...

2022-02-04 17:23 4337

Nanoform signs GMP manufacturing program with TargTex following formulation success

HELSINKI, Feb. 4, 2022 /PRNewswire/ -- Nanoform, an innovative nanoparticle medicine enabling company, today announced it has signed a GMP1 manufacturing program (clinical development) to enhance TargTex's Glioblastoma multiforme drug candidate. The program starts with a PoP (Proof of Process) ph...

2022-02-04 15:54 3172

New Zealand's Medsafe Grants Provisional Approval for Novavax' COVID-19 Vaccine

Nuvaxovid™ is the first protein-based COVID-19 vaccine to receive provisional approval for distribution inNew Zealand GAITHERSBURG, Md., Feb. 4, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for ser...

2022-02-04 06:54 2565

Mentice publishes the company's year-end report for the period January-December 2021

STOCKHOLM, Feb. 3, 2022 /PRNewswire/ -- Continued strength with net sales growth above 30% despite the pandemic Fourth quarter (October-December 2021) * Order intake amounted to 73.7 (73.1) MSEK. * Net sales amounted to 67.7 (45.9) MSEK. * Operating income for the period before depreciation...

2022-02-03 15:37 2161

CordenPharma Completes Acquisition of Three Manufacturing Facilities from Vifor Pharma

LUXEMBOURG, Feb. 2, 2022 /PRNewswire/ -- CordenPharma, a leading, full-service Contract Development & Manufacturing Organization (CDMO) supplying APIs, Excipients, Drug Products, and associated Packaging services, announced today the completion of the acquisition of three manufacturing facilities...

2022-02-02 11:00 2929

World's most trusted source for chemistry information, CAS, launches major biology expansion

CAS SciFinder Discovery Platform™ redefines its role in drug discovery with the inclusion of unique biosequence data collection and capabilities COLUMBUS, Ohio, Feb. 2, 2022 /PRNewswire/ -- CAS, a division of the American Chemical Society specializing in scientific information solutions, announce...

2022-02-02 10:42 2795

New Business Partnership Between Otsuka Pharmaceutical and Digital Health VR Technology Developer Jolly Good

TOKYO, Feb. 1, 2022 /PRNewswire/ -- With the aim of building a regional cooperative mental health platform, Jolly Good Inc. (Chuo-ku,Tokyo; CEO: Kensuke Joji) and Otsuka Pharmaceutical Co., Ltd. (Chiyoda-ku, Tokyo; President and Representative Director:Makoto Inoue) have signed an agreement for ...

2022-02-01 21:00 2159

Cytiva fuels biotech development in Australia and New Zealand

* VivaZome Therapeutics wins top prize with its potential to provide off-the-shelf regenerative medicines. * Part of Cytiva's BioChallenge global series, the inaugural challenge for the Australia and New Zealand region received 32 applications from various universities and companies. SYDNEY, F...

2022-02-01 07:00 2967

DEBIOPHARM AND ASPEN PARTNER TO LAUNCH PROSTATE CANCER DRUG TRELSTAR® IN SOUTH AFRICA

LAUSANNE, Switzerland and DURBAN, South Africa, Feb. 1, 2022 /PRNewswire/ -- Debiopharm (www.debiopharm.com ), a Swiss biopharmaceutical company andAspen, a South African headquartered multinational pharmaceutical company announced today their partnership to  launch Tr...

2022-02-01 06:00 3160

Denovo Biopharma LLC Announces FDA Approval of IND to Initiate First Biomarker-Guided Global CNS Clinical Trial for Treatment-Resistant Depression (TRD)

SAN DIEGO, Feb. 1, 2022 /PRNewswire/ -- Denovo Biopharma LLC ("Denovo"), a pioneer in applying precision medicine to the development of innovative therapies, today announced that the FDA has authorized the company's investigational new drug (IND) application of DB104 (liafensine) for treatment-r...

2022-02-01 05:30 2375

Novavax Submits Request to the U.S. FDA for Emergency Use Authorization of COVID-19 Vaccine

- NVX-CoV2373 demonstrated overall efficacy of ~90% in PREVENT-19 clinical trial conducted during the emergence of variant strains GAITHERSBURG, Md., Feb. 1, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vac...

2022-02-01 04:06 3416

Exopharm and Astellas Institute for Regenerative Medicine (AIRM) Sign Master Collaborative Services Agreement

* Astellas Institute for Regenerative Medicine (AIRM) is a subsidiary of Astellas Pharma Inc., a top 20 global pharmaceutical company * Initial services will seek to validate Exopharm's LEAP, LOAD and EVPS technology platforms to manufacture exosomes for Astellas, firstly at Exopharm's facili...

2022-01-31 19:00 1684

HanBio Therapeutics Announces the Completion of a US$40 Million Series A Financing Led by OrbiMed and Hankang Capital

SHANGHAI, Jan. 28, 2022 /PRNewswire/ -- HanBio Therapeutics ("HanBio"), a biotechnology company committed to researching and developing next generation transformative medicines, today announced that it has completed aUS$40 million Series A financing to advance the preclinical and clinical develop...

2022-01-29 11:37 6807

Aurealis Therapeutics and Xbiome Enter into a License and Collaboration Agreement for Aurealis Four-in-One Diabetic Foot Ulcer and Inflammatory Disease Cell and Gene Therapy AUP-16 in Greater China

BASEL, Switzerland, KUOPIO, Finland, and SHENZHEN, China, Jan. 29, 2022 /PRNewswire/ -- Aurealis Therapeutics, a synthetic biology company developing groundbreaking four-in-one cell and gene therapies and Xbiome, an AI-based microbiome drug development company, today announced that the two compan...

2022-01-29 05:28 4115

CTB001, Bioheng auto CAR - T Product, received Orphan Drug Designation (ODD) from the U.S. FDA

NANJING, China, Jan. 28, 2022 /PRNewswire/ -- Recently, Nanjing Bioheng Biotech Co.,Ltd. ( hereinafter referred to as Bioheng) announced that its anti-claudin 18.2 autologous CAR-T cell therapy product CTB001 received Orphan Drug Designation (ODD) from the Food and Drug Administration (FDA) for t...

2022-01-28 22:00 2871
1 ... 200201202203204205206 ... 318